72 related articles for article (PubMed ID: 25012543)
1. Genetic variability of VEGF pathway genes in six randomized phase III trials assessing the addition of bevacizumab to standard therapy.
de Haas S; Delmar P; Bansal AT; Moisse M; Miles DW; Leighl N; Escudier B; Van Cutsem E; Carmeliet P; Scherer SJ; Pallaud C; Lambrechts D
Angiogenesis; 2014 Oct; 17(4):909-20. PubMed ID: 25012543
[TBL] [Abstract][Full Text] [Related]
2. Nonsynonymous mutations in VEGF receptor binding domain alter the efficacy of bevacizumab treatment.
Ahamed A; Samanta A; Alam SSM; Mir SA; Jamil Z; Ali S; Hoque M
J Cell Biochem; 2024 Feb; 125(2):e30515. PubMed ID: 38213080
[TBL] [Abstract][Full Text] [Related]
3. Genetic variants in hypoxia-inducible factor pathway are associated with colorectal cancer risk and immune infiltration.
Guo M; Lin J; Cao X; Zhou J; Ben S; Chen S; Chu H; Miao L; Li S; Gu D
J Cell Mol Med; 2024 Jan; 28(1):e18019. PubMed ID: 37994607
[TBL] [Abstract][Full Text] [Related]
4. The multifaceted activity of VEGF in angiogenesis - Implications for therapy responses.
Moens S; Goveia J; Stapor PC; Cantelmo AR; Carmeliet P
Cytokine Growth Factor Rev; 2014 Aug; 25(4):473-82. PubMed ID: 25169850
[TBL] [Abstract][Full Text] [Related]
5. Randomized trial of TAS-102 for refractory metastatic colorectal cancer.
Mayer RJ; Van Cutsem E; Falcone A; Yoshino T; Garcia-Carbonero R; Mizunuma N; Yamazaki K; Shimada Y; Tabernero J; Komatsu Y; Sobrero A; Boucher E; Peeters M; Tran B; Lenz HJ; Zaniboni A; Hochster H; Cleary JM; Prenen H; Benedetti F; Mizuguchi H; Makris L; Ito M; Ohtsu A;
N Engl J Med; 2015 May; 372(20):1909-19. PubMed ID: 25970050
[TBL] [Abstract][Full Text] [Related]
6. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study.
Tabernero J; Yoshino T; Cohn AL; Obermannova R; Bodoky G; Garcia-Carbonero R; Ciuleanu TE; Portnoy DC; Van Cutsem E; Grothey A; Prausová J; Garcia-Alfonso P; Yamazaki K; Clingan PR; Lonardi S; Kim TW; Simms L; Chang SC; Nasroulah F;
Lancet Oncol; 2015 May; 16(5):499-508. PubMed ID: 25877855
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant chemotherapy after preoperative (chemo)radiotherapy and surgery for patients with rectal cancer: a systematic review and meta-analysis of individual patient data.
Breugom AJ; Swets M; Bosset JF; Collette L; Sainato A; Cionini L; Glynne-Jones R; Counsell N; Bastiaannet E; van den Broek CB; Liefers GJ; Putter H; van de Velde CJ
Lancet Oncol; 2015 Feb; 16(2):200-7. PubMed ID: 25589192
[TBL] [Abstract][Full Text] [Related]
8. Genetic variants in VEGF pathway genes in neoadjuvant breast cancer patients receiving bevacizumab: Results from the randomized phase III GeparQuinto study.
Hein A; Lambrechts D; von Minckwitz G; Häberle L; Eidtmann H; Tesch H; Untch M; Hilfrich J; Schem C; Rezai M; Gerber B; Dan Costa S; Blohmer JU; Schwedler K; Kittel K; Fehm T; Kunz G; Beckmann MW; Ekici AB; Hanusch C; Huober J; Liedtke C; Mau C; Moisse M; Müller V; Nekljudova V; Peuteman G; Rack B; Rübner M; Van Brussel T; Wang L; Weinshilboum RM; Loibl S; Fasching PA
Int J Cancer; 2015 Dec; 137(12):2981-8. PubMed ID: 26100253
[TBL] [Abstract][Full Text] [Related]
9. IL8 polymorphisms and overall survival in pazopanib- or sunitinib-treated patients with renal cell carcinoma.
Xu CF; Johnson T; Garcia-Donas J; Choueiri TK; Sternberg CN; Davis ID; Bing N; Deen KC; Xue Z; McCann L; Esteban E; Whittaker JC; Spraggs CF; Rodríguez-Antona C; Pandite LN; Motzer RJ
Br J Cancer; 2015 Mar; 112(7):1190-8. PubMed ID: 25695485
[TBL] [Abstract][Full Text] [Related]
10. Meox2/Tcf15 heterodimers program the heart capillary endothelium for cardiac fatty acid uptake.
Coppiello G; Collantes M; Sirerol-Piquer MS; Vandenwijngaert S; Schoors S; Swinnen M; Vandersmissen I; Herijgers P; Topal B; van Loon J; Goffin J; Prósper F; Carmeliet P; García-Verdugo JM; Janssens S; Peñuelas I; Aranguren XL; Luttun A
Circulation; 2015 Mar; 131(9):815-26. PubMed ID: 25561514
[TBL] [Abstract][Full Text] [Related]
11. A macrophage-dominant PI3K isoform controls hypoxia-induced HIF1α and HIF2α stability and tumor growth, angiogenesis, and metastasis.
Joshi S; Singh AR; Zulcic M; Durden DL
Mol Cancer Res; 2014 Oct; 12(10):1520-31. PubMed ID: 25103499
[TBL] [Abstract][Full Text] [Related]
12. Mismatch repair deficiency endows tumors with a unique mutation signature and sensitivity to DNA double-strand breaks.
Zhao H; Thienpont B; Yesilyurt BT; Moisse M; Reumers J; Coenegrachts L; Sagaert X; Schrauwen S; Smeets D; Matthijs G; Aerts S; Cools J; Metcalf A; Spurdle A; ; Amant F; Lambrechts D
Elife; 2014 Aug; 3():e02725. PubMed ID: 25085081
[TBL] [Abstract][Full Text] [Related]
13. CEBP-β and PLK1 as Potential Mediators of the Breast Cancer/Obesity Crosstalk: In Vitro and In Silico Analyses.
Accattatis FM; Caruso A; Carleo A; Del Console P; Gelsomino L; Bonofiglio D; Giordano C; Barone I; Andò S; Bianchi L; Catalano S
Nutrients; 2023 Jun; 15(13):. PubMed ID: 37447165
[TBL] [Abstract][Full Text] [Related]
14. An Immune-Related Prognostic Signature Predicts Overall Survival in Stomach Adenocarcinomas.
Zhou K; Hu N; Hong Y; Wu X; Zhang J; Lai H; Zhang Y; Wu F
Front Genet; 2022; 13():903393. PubMed ID: 35677557
[TBL] [Abstract][Full Text] [Related]
15. Genetic Variant of CXCR1 (rs2234671) Associates with Clinical Outcome in Perihilar Cholangiocarcinoma.
Lurje I; Czigany Z; Bednarsch J; Gaisa NT; Dahl E; Knüchel R; Miller H; Ulmer TF; Strnad P; Trautwein C; Tacke F; Neumann UP; Lurje G
Liver Cancer; 2022 Apr; 11(2):162-173. PubMed ID: 35634429
[TBL] [Abstract][Full Text] [Related]
16. VEGF-A, VEGFR1 and VEGFR2 single nucleotide polymorphisms and outcomes from the AGITG MAX trial of capecitabine, bevacizumab and mitomycin C in metastatic colorectal cancer.
Chionh F; Gebski V; Al-Obaidi SJ; Mooi JK; Bruhn MA; Lee CK; Chüeh AC; Williams DS; Weickhardt AJ; Wilson K; Scott AM; Simes J; Hardingham JE; Price TJ; Mariadason JM; Tebbutt NC
Sci Rep; 2022 Jan; 12(1):1238. PubMed ID: 35075138
[TBL] [Abstract][Full Text] [Related]
17. The cancer angiogenesis co-culture assay: In vitro quantification of the angiogenic potential of tumoroids.
Truelsen SLB; Mousavi N; Wei H; Harvey L; Stausholm R; Spillum E; Hagel G; Qvortrup K; Thastrup O; Harling H; Mellor H; Thastrup J
PLoS One; 2021; 16(7):e0253258. PubMed ID: 34234354
[TBL] [Abstract][Full Text] [Related]
18. Molecular Bases of Mechanisms Accounting for Drug Resistance in Gastric Adenocarcinoma.
Marin JJG; Perez-Silva L; Macias RIR; Asensio M; Peleteiro-Vigil A; Sanchez-Martin A; Cives-Losada C; Sanchon-Sanchez P; Sanchez De Blas B; Herraez E; Briz O; Lozano E
Cancers (Basel); 2020 Jul; 12(8):. PubMed ID: 32751679
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of bevacizumab-containing chemotherapy in metastatic colorectal cancer and
Novillo A; Gaibar M; Romero-Lorca A; Gilsanz MF; Beltrán L; Galán M; Antón B; Malón D; Moreno A; Fernández-Santander A
World J Gastroenterol; 2020 Apr; 26(16):1979-1986. PubMed ID: 32390708
[TBL] [Abstract][Full Text] [Related]
20. [
Sharma R; Valls PO; Inglese M; Dubash S; Chen M; Gabra H; Montes A; Challapalli A; Arshad M; Tharakan G; Chambers E; Cole T; Lozano-Kuehne JP; Barwick TD; Aboagye EO
Eur J Nucl Med Mol Imaging; 2020 May; 47(5):1239-1251. PubMed ID: 31754793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
